Levofloxacin Market Forecast Reveals Rapid Growth in Asia-Pacific Region and Advancements in Targeted Therapies
January 29, 2024 11:15 ET
|
Research and Markets
Dublin, Jan. 29, 2024 (GLOBE NEWSWIRE) -- The "Levofloxacin Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering. Global attention turns to the recent...
Pyelonephritis Treatment Market Worth US$ 351.35 Mn By 2030, A Survey By Reports Insights
May 28, 2023 06:00 ET
|
REPORTSINSIGHTS CONSULTING PVT LTD
New York, May 28, 2023 (GLOBE NEWSWIRE) -- According to a recent report by Reports Insights, the Pyelonephritis treatment market is poised for strong expansion and is expected to reach USD 351.35...
Global Antibiotics Market Report 2023: Growing Development Pipeline and Positive Clinical Trial Results Bode Well for Industry
April 27, 2023 04:58 ET
|
Research and Markets
Dublin, April 27, 2023 (GLOBE NEWSWIRE) -- The "Global Antibiotics Market - Distribution by Type of Drug Class, Target Disease Indication, Type of Therapy (Monotherapies and Combination Therapies),...
China Levofloxacin Market Report 2021: CAGR of Sales Value is -4.75% from 2016 to 2020 - Forecasts to 2025
July 01, 2021 07:03 ET
|
Research and Markets
Dublin, July 01, 2021 (GLOBE NEWSWIRE) -- The "Investigation Report on China's Levofloxacin Market 2021-2025" report has been added to ResearchAndMarkets.com's offering. Levofloxacin, developed by...
Global Urinary Tract Infection Treatment Markets, 2020-2027 - Market for Penicillin and Combination Drugs Segment to Grow at Highest Rate
February 09, 2021 04:38 ET
|
Research and Markets
Dublin, Feb. 09, 2021 (GLOBE NEWSWIRE) -- The "Urinary Tract Infection Treatment Market Forecast to 2027 - COVID-19 Impact and Global Analysis By Drug Class, Indication, Distribution Channel, and...
Raptor Pharmaceutical Launches QUINSAIR™ in Europe
April 11, 2016 07:05 ET
|
Raptor Pharmaceutical Inc
NOVATO, Calif., April 11, 2016 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced its first commercial sale of QUINSAIR™ (levofloxacin inhalation solution) in Germany and...
Raptor Pharmaceutical Corp. Expands Rare Disease Portfolio With the Acquisition of Quinsair(TM)
August 20, 2015 17:16 ET
|
Raptor Pharmaceutical Inc
First Inhaled Fluoroquinolone Therapy for Patients with Cystic Fibrosis
Approval Received in the European Union and Canada
Expansion of Pipeline with Multiple Late-Stage Orphan Indication...
U.S Bacterial Conjunctivitis Drugs Market Will Reach US& 439.8 Million in 2024 by Persistence Market Research
July 13, 2015 03:53 ET
|
Persistence Market Research
New York, July 13, 2015 (GLOBE NEWSWIRE) -- According to a new market report published by Persistence Market Research "The U.S Market Study on Bacterial Conjunctivitis Drugs: fluoroquinolones to be...